Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Publikováno v:
Cytotherapy. 16:1584-1589
Background aims Stem cell collection can be a major component of overall cost of autologous stem cell transplantation (ASCT). Plerixafor is an effective agent for mobilization; however, it is often reserved for salvage therapy because of its high cos
Publikováno v:
Cytotherapy. 15:1118-1125
Background aims The purpose of this study was to observe the outcome of co-transfusion of umbilical cord multipotent stromal cells (UC-MSC) and allogeneic hematopoietic stem cells in the treatment of heavily-transfused patients with severe aplastic a
Autor:
Norihiro Kokudo, Kazuhiro Kakimi, Kiyoshi Hasegawa, Mayumi Hoshikawa, Taku Aoki, Hirokazu Matsushita
Publikováno v:
Cytotherapy. 19(4)
Background aims The outcome for pancreatic cancer after surgery remains highly unsatisfactory, and development of more effective therapies is urgently needed. Therefore, we conducted a phase I clinical study of a novel combination of gemcitabine (GEM
Autor:
Evarist Feliu, Jordi Juncà, Anna Ester, Joan-Ramon Grifols, Susana Vives, David Gallardo, Ramon Guardia, Christelle Ferra, Juan-Manuel Sancho, Mireia Morgades, Monsterrat Batlle, Josep-Maria Ribera, Fuensanta Millá
Publikováno v:
Cytotherapy. 14:823-829
Failure in mobilization of peripheral blood (PB) stem cells is a frequent reason for not performing hematopoietic stem cell transplantation (HSCT). Early identification of poor mobilizers could avoid repeated attempts at mobilization, with the admini
Publikováno v:
Cytotherapy. 14:467-472
Background aims. Plerixafor was recently approved for use in combination with granulocyte – colony-stimulating factor (G-CSF) for hematopoietic progenitor cell (HPC) collection by apheresis in adults with multiple myeloma (MM) or nonHodgkin lymphom
Publikováno v:
Cytotherapy. 14:350-358
Little is known of the effect of anticoagulation on peripheral blood progenitor cell (PBPC) harvest during large-volume leukapheresis (LVL). Because of the interaction of heparin with stromal cell-derived factor (SDF)-1α, it has been proposed that a
Publikováno v:
Cytotherapy. 12:678-683
Background aims. Aplastic anemia (AA) is a rare but potentially life-threatening disease. There is a need for the development of new, more effective and less toxic therapies for treating AA. The safety and efficacy of an immune cell-based therapy for
Publikováno v:
Cytotherapy. 11:362-371
The purpose of this study was to observe the efficacy and toxicity of etoposide at two dose levels for peripheral blood stem cell (PBSC) mobilization and disease debulking in patients with malignancy. Simultaneously, factors affecting the yield of CD
Autor:
Jordi Sierra, E. Moreno, Javier Briones, José Luis Piñana, Julio Delgado, Rodrigo Martino, A. Marco, Salut Brunet, Anna Sureda, David Valcárcel
Publikováno v:
CYTOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background In 2003, oral fludarabine was introduced for the treatment of patients with hematologic malignancies as an alternative to its intravenous (i.v.) formulation. In an attempt to simplify the management of patients undergoing reduced intensity
Publikováno v:
Cytotherapy. 10:45-53
Allogeneic stem cell transplantation in multiple myeloma (MM) is controversial because treatment-related mortality and relapse remain a substantial challenge.Patients with symptomatic MM responsive to therapy received myeloablative conditioning with